AKT1 and breast carcinoma: TAMs also secrete the cytokine interleukin (IL)-10 and CC-chemokine ligand 2 (CCL2), thus enacting a three-pronged strategy to impact the activity of the C-Jun N-terminal kinases (C-JNK), STAT3, BCL-2 and PI3K/AKT/mTOR signaling pathways to mediate paclitaxel (PTX) and tamoxifen resistance in breast cancer [41,42].